2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Clinical Procedures, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Immunology, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, Indolent Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3981 Bispecific antibody therapy outcomes in a racially diverse relapsed/refractory multiple myeloma cohort shows differences in neutropenia and response to tandem bsab treatment

Joshua Kassner, MD, Susan Karass, DO2, Tobechukwu Okobi, MD3, Emmanuel Bugarin Estrada, MD, MSc4, Soeb Usta, MD5, Vera Jokic, MD6, Theresia Akhlaghi, MD7, Neela Easton, MD8, Joshua A Fein, MD9, Michelle Pasciolla, PharmD10, Marina Barsoum, PharmD11, Yuri Kim, PharmD12, Marina Reed, PharmD13, Victor Zepeda, MD14, Mateo Mejia Saldarriaga, Assistant Professor15, Roger Pearse, MD16, Ruben Niesvizky, MD17, Perry Cook, MD18, Mark Bustoros, MD19
1 Weill Cornell Medical College, New York, New York, United States
2 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
3 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
4 University of Miami Jackson Memorial Hospital, Miami, Florida, United States
5 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
6 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
7 Weill Cornell Medical College, New York, New York, United States
8 Weill Cornell Medical College, New York, New York, United States
9 Weill Cornell Medical College, New York, New York, United States
10 Weill Cornell Medical College, New York, New York, United States
11 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
12 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
13 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
14 Weill Cornell Medical College, New York, New York, United States
15 Weill Cornell Medical College, New York, New York, United States
16 Weill Cornell Medical College, New York, New York, United States
17 Weill Cornell Medical College, New York, New York, United States
18 New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
19 Weill Cornell Medical College, New York, New York, United States

Background. Bispecific antibodies (BsAb) are standard for relapsed/refractory multiple myeloma (RRMM), but landmark trials such as MajesTEC-1 (NCT04557098) excluded ECOG performance status (PS) ≥2 and enrolled few Black patients. Whether trial-level efficacy, toxicity and supportive care are reproduced outside that population is undefined, as is whether progression reflects target escape or T-cell exhaustion, which determines next-line choice. We report outcomes in an RRMM cohort enriched for Black patients, compared by race, with paired sequential courses. 

  

Methods. In this two-center retrospective study, all 90 patients receiving a BsAb for RRMM at a community safety-net hospital and an academic center from October 2021 to June 2026 were analyzed (109 courses); 19 (21%) received two BsAb courses. Response was assessed per International Myeloma Working Group criteria, inflammatory complications by ASTCT 2019, and infection by CTCAE v5.0. Neutrophil metrics used a fixed 90-day window, equalizing observation time; IVIG receipt was binary, so those analyses used a day-90 landmark. Comparisons used Fisher exact, Mann-Whitney, McNemar, log-rank and logistic regression. 

Results. Median age was 72 years (IQR 62-77); 41% were ≥75 and ECOG PS ≥2 in 38%. Fifty-four (60%) were White, 30 (33%) Black, 6 (7%) Asian; 30 (33%) community-treated. Median prior lines was 4 (IQR 3-6); 89% were triple-class exposed. Median progression-free survival (PFS) was 11.5 months (95% CI 6.9-19.3) versus 11.3 in MajesTEC-1; overall response rate (ORR) was 73% (66/90) versus 63% and ≥CR 53% versus 39%. CRS occurred in 62% (grade ≥2, 13%) and grade ≥3 infection in 36%. Median OS was 33.4 months at 22.4 months follow-up (95% CI 13.1 to not reached). IVIG was given to 73% (66/90) and was not associated with infection incidence (35% vs 38%, p=0.81) but tracked lower infection-related mortality (8% vs 25%, p=0.062). 

Efficacy was preserved across race (White vs Black vs Asian): ORR 74% vs 73% vs 67%, p=0.93; ≥CR 46% vs 67% vs 50%, p=0.20; median PFS 11.5 vs 11.7 vs 6.7 months, p=0.72. Immune effector toxicity did not differ: any-grade CRS 69%, 48% and 67% (p=0.19), any-grade ICANS 19%, 10% and 33% (p=0.32), with comparable tocilizumab use (44%, 47%, 67%; p=0.59). 

Black and White patients did not differ in PFS (11.7 vs 11.5 months, HR 0.94, 0.51-1.75) or OS (not reached vs 20.3 months, HR 0.51, 0.22-1.19), and non-relapse mortality was identical (17% vs 19%, p=1.00). From equivalent baseline ANC (2.88 vs 3.10 K/uL, p=0.29), Black patients reached lower 90-day nadirs (0.73 vs 1.50, p=0.023), crossed ANC <0.5 more often (46% vs 19%, p=0.019) and received 2.5-fold more G-CSF (60% vs 24%; adjusted OR 6.04, p=0.008), yet grade ≥3 infection was no higher (23% vs 44%, p=0.09). IVIG was delivered equally (73% vs 76%, p=0.80). 

On rechallenge with a different BsAb agent after disease progression (n=19, White=9, Black=6, Asian=2), response and depth were preserved (ORR 58% vs 63% and ≥CR 37% vs 32%, p >0.99 for both) between first and second BsAb treatments, respectively. Two patients received BCMA targeted therapy sequentially and failed to have a response in their second course. Benefit tracked when BsAb target was switched during second agent's course (ORR 79%, 11/14, BCMA to GPRC5D-directed vs 20%, 1/3, GPRC5D to BCMA-directed; p=0.19), and 4/6 patients with a best response of progressive disease (PD) through the first BsAb course responded to a class-switched agent. Median duration of the first BsAb course was 6.3 months (IQR 1.2–9.0 months) and median time between end of the first course and start of the second course was 1.3 months. Neither first-course duration (≥6 months: 70% vs ≤6 months 56%, p=65) nor treatment-free interval (p=0.71) predicted second-course response. 

 

Conclusions. BsAb therapy in this racially diverse real-world cohort produced PFS similar to landmark trials with no excess CRS or infection, in a population where more than a third had ECOG PS ≥2 and a third were community-treated; efficacy, survival and non-relapse mortality were preserved across race. Black patients crossed neutropenia thresholds more often and received more growth factor with no excess infection, suggesting growth factor utilization mitigates infectious complications. On rechallenge, depth of response was preserved and benefit depended on the target antigen of the second agent rather than duration of the first, supporting class switching at progression. 

Joshua Kassner, MD: No relevant conflicts of interest to declare.